* If you want to update the article please login/register
Septic sequestration disorder, intrahepatic cholestasis, gallstones, non-cirrhotic portal hypertension, chronic sickle disease, and cirrhosis can all be present, as well as complications of the disease management, including secondary iron overload and viral hepatitis. One of the signs for transplant is Stem cell transplantation, and the NIH SCD hepatopathy is the only cure for SCD. We currently don't know if stem cell transplant reverses SCD liver disease, so we need to investigate and compare the characteristics of SCD liver disease before and post stem cell transplantation, as well as transplant ineligible patients. Hence, all patients in the transplant eligible arm will have liver biopsy pre and 12-24 months post transplantation. When clinically indicated, Transplant ineligible patients will be referred to liver biopsy. The aim of the research was to use sickle cell disease as a predictor of liver disease progression and regression.
Source link: https://clinicaltrials.gov/ct2/show/NCT01950429
Wilson's disease, acute and chronic liver disease, B, C, D and E, primary biliary cirrhosis, primary sclerosing cholangitis, principal biliary cirrhosis, noncirrhotic portal hypertension, noncirrhotic portal hypertension, hepatocellular carcinoma, or cryptogenic or poorly defined forms of chronic liver disease are all common liver diseases such as acute and chronic liver disease, acute and chronic liver disease, Patients will first be seen in the outpatient clinic and undergo a medical history and physical examination. Patients will then be followed in the outpatient department at intervals that are appropriate for their clinical status. With research samples obtained, patients will be treated for an interim medical history and brief examination. Additional tissue biopsy may be obtained during a medically advised procedure, such as liver biopsy. Subjects who are eligible for other studies of their liver disease will be eligible for other research.
Source link: https://clinicaltrials.gov/ct2/show/NCT00001971
Rather than the steatosis or inflammation component, the primary goal will be on imaging biomarkers of nonalcoholic fatty liver disease's liver fibrosis component of nonalcoholic fatty liver disease. The explanation is that the fibrosis component is connected most closely to survival and other medical findings. In addition, vendor- or device-specific investigation biomarkers on other aspects of NAFLD, such as steatosis and possibly inflammation, will be included in Study 1.
Source link: https://clinicaltrials.gov/ct2/show/NCT04828551
Chronic liver disease is the most common cause of chronic aminotransferase elevations in the United States, and it is the most common cause of non-AIDS-related morbidity and mortality in PLWH. Although there are signs that both Hepatitis B and Hepatitis C infection are linked to an elevated course in PLWH, it is unknown if NAFLD is also increasing in PLWH. In addition, it will also establish a robust biospecimen bank and compare the accuracy of non-invasive assessments of advanced fibrosis in determining histologically reported advanced fibrosis in PLWH.
Source link: https://clinicaltrials.gov/ct2/show/NCT05023044
In a prospective case-control study, the use of selected exRNA biomarkers for diagnosis of hepatocellular cancer or biliary tract cancers in patients with cirrhosis will be evaluated. To aid in the identification of risk factors for liver cancer risk factors, a risk factor questionnaire will be used.
Source link: https://clinicaltrials.gov/ct2/show/NCT02908048
Pathological changes in liver architecture that result in cirrhosis can be triggered by a variety of liver disorders, culminating in cirrhosis. Although invasive liver biopsy was used to detect cirrhosis, magnetic resonance elastography has revolutionized liver biopsy by non-invasive techniques that require liver stiffness measurement. Implementing this technique would change the situation by eliminating the need for invasive liver biopsies in patients suspected of such disorders as suspected liver disease. Both common comorbidities of obesity are also present in this report. The aim of this research is to determine the effect of obstructive sleep apnea on the pathogenesis of nonalcoholic fatty liver disease. Latest evidence shows a potential correlation between OSA and severity of NASH and fibrosis, but the exact details of OSA-associated hypoxia in NAFLD remain unclear.
Source link: https://clinicaltrials.gov/ct2/show/NCT02565446
The relationship between colon polyps and NAFLD will be determined in phase I. Phase I: After collecting informed consent and confirming that the subject has met inclusion and exclusion criteria for the study, the research will use a questionnaire to be completed by the student. Subjects will be called by the PI or an AI to return to the clinic for additional testing methods, including a core liver biopsy, if they are identified as having one or more of the following: greater or equal to 5% steatosis on MRI or liver stiffness greater than 5. 7 kPa on Fibroscan®, or signs of fibrosis on MRE or LIF scores greater than 5. 0 kPa on Fibroscan®, or fibrosis The M probe operates between 25 and 65 mm below the skin surface, and the XL probe runs between 35 and 75 mm. In conjuncture with the MRI scan and post-processed by AIs within the BAMC Radiology Department, a MR elastography scan will be performed. Participants who qualify for a core liver biopsy based on the findings from the FibroScan and MRE/MRI LiverMultiScan's findings will be asked to return to specimen collection for further blood work prior to the liver biopsy. The outside expert pathologist will use the same scoring system as the local pathologist, so the local pathologist will use the same scoring system. The liver biopsy slides will be used to compare the FibroMeterTM NAFLD/VCTE test with liver fibrosis and the presence of NAFLD and NASH. FibroMeterTM is a non-invasive diagnostic test that measures the severity of fibrosis in the liver using patient clinical data and a custom blend of standard clinical lab findings, including platelets, AST, ALT, ferritin, glucose, and Alpha-2-Macroglobulin levels. Echosens will then use the FibroMeter test results to correlate with the morphometry analysis. The aim 3 patients who underwent or will perform colonoscopy as part of their regular medical care will have their AHLTA/CHCS records reviewed, and those with colon polyps or colon masses will be assessed against their imaging study results, in order to respond to their aim 3 subjects. Subjects undergoing a liver transplant will be referred to the research group members in the Cardiology clinic with the ability to enroll in Phase II of the program. The Cockcroft-Gault equation, no prior history of an allergic reaction to an intravenous CT comparison, and no objections have been found against the administration of sublingual nitroglycerin and nodal blocking agents, as shown by the Cockcroft-Gault equation. Prior to approving the CCTA acquisition, the CT technologist will be responsible for calling the on-call CT imaging specialist for CAC scores 400. In consultation with the on-call cardiac CT imaging specialist specializing in Appendix 3, the CT technologist's tube voltage and image acquisition protocoling will be selected by the CT technologist in accordance with the flowsheet that is included in Appendix 3. The following will be administered: orally, for HR > 70 bpm and SBP> 100 mm Hg, and nodal blocking agents> 100 mm Hg will be provided; for patients with HR 70 bpm and SBP > 100 mm Hg at the time of assessment, there will be no such blockers. For all scans with total IV contrast volume of 105-125 mL, a triphasic injection procedure consisting of 75 million units of IV contrast and 40 mL of 50% contrast mixed with normal saline chased with normal saline at a flow rate of 5 mL/second will be used. Transthoracic Echocardiography (DA) : All subjects who meet inclusion criteria for a percutaneous liver biopsy and agreed to phase II will be analyzed for cardiovascular diastolic function using Doppler devices, including 2D and 3D transthoracic echocardiography. EndoPAT: Endothelial function in patients who are eligible for liver biopsy and consent to phase II using the EndoPAT 2000® will be determined on the same day as the CCTA for subject convenience.
Source link: https://clinicaltrials.gov/ct2/show/NCT03142867
Chronic hepatitis B virus infection is a global public health issue that has placed more than 250 million people at risk of death from cirrhosis and liver cancer. Chronic hepatitis B patients are expected to live and be well-lived by preventing disease progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. In Asian people with CHB, similar to Western countries, the prevalence of the fatty liver disease is approximately 14-6 percent. In CHB patients, a significant correlation between steatohepatitis and advanced fibrosis was found. Patients with CHB receiving antiviral therapy have been shown to have an elevated risk of fibrosis progression in patients with Fatty liver disease. Patients with potential concurrent NAFLD with tenofovir disoproxil fumarate for CHB were less likely to experience fibrosis disease recovery despite viral suppression, according to a follow-up study of cirrhotic patients treated with tenofovir disoproxil fumarate for CHB. Lower body mass index was positively linked to fibrosis in CHB patients who had undetectable HBV viral load during long-term nucleoside analogue therapy, according to another prospective study. However, there are no studies on the effects of concurrent fatty liver disease on clinical outcomes in CHB's comprehensive therapy. According to improve our knowledge of concurrent fatty liver disease in these patients receiving antiviral therapy, this longitudinal cohort study sought to determine the effects of concurrent fatty liver disease on overall survival and liver-related complications among CHB patients receiving antiviral therapy to increase our understanding of the prognostic value of concurrent fatty liver disease.
Source link: https://clinicaltrials.gov/ct2/show/NCT05317260
An excess accumulation of fat in the liver that occurs when children's diet and exercise habits raise the genetic risk with which they were born. Excess fat in the liver raises the risk of diabetes and heart disease, as well as the likelihood that a liver transplant is required. Increasing free sugar intake in children with NAFLD has previously shown that lowering intake of free sugars to very low levels, reduces the amount of fat stored in the liver, and improves the metabolic health of children with NAFLD. This single site randomised clinical trial will determine if following a diet very low in free sugars right before puberty, a time of increased metabolic disruption, may help to prevent NAFLD in children known to be at risk of NAFLD. This trial will look at free-living Hispanic children with overweight or obesity because their risk of NAFLD has been well documented compared to non-Hispanic children. Enrollment will include children aged 6-9 years and Tanner stage 1 living in the Atlanta metropolitan area. A one-year nutritional supplement, along with nutritional coaching and family-centered goal setting; a one-month supply of a low-free sugar diet for the entire family; and a nutritionist-led grocery shopping trips every 3 months thereafter. The primary outcome at year one is an MRI-assessed change in the amount of liver fat from baseline. The incidence of NAFLD in the intervention group vs. control group will be determined at 24 months.
Source link: https://clinicaltrials.gov/ct2/show/NCT05292352
Non-alcoholic fatty liver disease is the most common hepatic disease in the Western world, and is a leading cause of liver-related morbidity and mortality. By utilizing a metabolomics-based dynamic paradigm, we propose a pilot study to determine patients with NAFLD's dietary response to a standardized food challenge. We will start with up to 50 patients with NAFLD and compare them to 12 controls with metabolic syndrome without NAFLD, as well as 12 healthy controls in this research. Following completion of recruitment, plasma will be separated and stored in 80 C. , with metabolites of concern identified, and individual metabolites determined and normalized to their pre-prandial average. The study findings will hopefully reveal novel metabolic signs of disease and reveal new signaling pathways specific to NAFLD that are mostly active under fed state conditions.
Source link: https://clinicaltrials.gov/ct2/show/NCT02520609
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions